IVA
Price:
$2.615
Market Cap:
$218.05M
Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS), and other diseases. Its lead product candidate is Lanifibranor, which has completed Phase IIb clinical trial to treat NASH. The company also develops Odiparcil, which has completed Phase IIa clinical trial for the treatment of MPS VI subtype disease. In addition, it has a pipeline of earlier stage programs in oncology and other diseases. The company has strategic collaboration with AbbVie for the treatment of autoimmune diseases; and Boehringer Ingelheim International GmbH for developing...[Read more]
Industry
Biotechnology
IPO Date
2020-07-10
Stock Exchange
NASDAQ
Ticker
IVA
According to Inventiva S.A.’s latest financial reports and current stock price. The company's current Enterprise Value is 228.20M. This represents a change of 85.69% compared to the average of 122.89M of the last 4 quarters.
The mean historical Enterprise Value of Inventiva S.A. over the last ten years is 193.98M. The current 228.20M Enterprise Value has changed 11.66% with respect to the historical average. Over the past ten years (40 quarters), IVA's Enterprise Value was at its highest in in the June 2020 quarter at 421.79M. The Enterprise Value was at its lowest in in the January 2013 quarter at 0.
Average
193.98M
Median
180.74M
Minimum
94.19M
Maximum
394.08M
Discovering the peaks and valleys of Inventiva S.A. Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 72.15%
Maximum Annual Enterprise Value = 394.08M
Minimum Annual Increase = -69.44%
Minimum Annual Enterprise Value = 94.19M
Year | Enterprise Value | Change |
---|---|---|
2023 | 195.60M | 62.43% |
2022 | 120.42M | -69.44% |
2021 | 394.08M | 27.35% |
2020 | 309.45M | 24.92% |
2019 | 247.71M | 33.26% |
2018 | 185.89M | 61.80% |
2017 | 114.89M | -34.57% |
2016 | 175.60M | 72.15% |
2015 | 102.00M | 8.29% |
2014 | 94.19M | 11.47% |
The current Enterprise Value of Inventiva S.A. (IVA) is less than than its 3-year, less than than its 5-year, and greater than its 10-year historical averages
3-year avg
236.70M
5-year avg
253.45M
10-year avg
193.98M
Inventiva S.A.’s Enterprise Value is less than Mineralys Therapeutics, Inc. (523.81M), greater than Eliem Therapeutics, Inc. (119.64M), greater than Anebulo Pharmaceuticals, Inc. (36.46M), less than Janux Therapeutics, Inc. (2.64B), less than Rezolute, Inc. (276.11M), less than Monte Rosa Therapeutics, Inc. (439.72M), less than NewAmsterdam Pharma Company N.V. (1.37B), less than Cullinan Oncology, Inc. (630.54M), greater than Compass Therapeutics, Inc. (182.75M), less than Arcellx, Inc. (4.79B), greater than Ventyx Biosciences, Inc. (80.09M), less than Immunocore Holdings plc (1.56B), less than Vaxcyte, Inc. (10.01B), less than DICE Therapeutics, Inc. (1.82B), greater than Verrica Pharmaceuticals Inc. (69.50M), greater than LianBio (-66141903.00), less than Edgewise Therapeutics, Inc. (3.01B), greater than Vigil Neuroscience, Inc. (98.69M), greater than Innate Pharma S.A. (92.12M), greater than HCW Biologics Inc. (34.47M), greater than Inhibrx Biosciences, Inc. (9.32M),
Company | Enterprise Value | Market cap |
---|---|---|
523.81M | $621.09M | |
119.64M | $342.68M | |
36.46M | $37.86M | |
2.64B | $2.64B | |
276.11M | $284.50M | |
439.72M | $521.60M | |
1.37B | $1.87B | |
630.54M | $730.17M | |
182.75M | $205.01M | |
4.79B | $4.89B | |
80.09M | $130.81M | |
1.56B | $1.61B | |
10.01B | $11.04B | |
1.82B | $2.27B | |
69.50M | $45.35M | |
-66141903.00 | $34.47M | |
3.01B | $3.05B | |
98.69M | $130.41M | |
92.12M | $131.95M | |
34.47M | $29.12M | |
9.32M | $203.82M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Inventiva S.A. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Inventiva S.A. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the Enterprise Value?
How can you use the Enterprise Value?
What is Inventiva S.A.'s Enterprise Value?
What is the highest Enterprise Value for Inventiva S.A. (IVA)?
What is the 3-year average Enterprise Value for Inventiva S.A. (IVA)?
What is the 5-year average Enterprise Value for Inventiva S.A. (IVA)?
How does the current Enterprise Value for Inventiva S.A. (IVA) compare to its historical average?